Lyell Immunopharma, Inc. Earnings Per Share, Basic and Diluted
Lyell Immunopharma, Inc. (LYEL) reported Earnings Per Share, Basic and Diluted of -$0.20 per share for the 3-month period ending 2021-09-30, per its 10-Q filed 2021-11-12.
Discontinued › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasicAndDiluted · last filed 2021-11-12
- Lyell Immunopharma, Inc. earnings per share, basic and diluted for the quarter ending 2021-09-30 was -$0.20.
- Lyell Immunopharma, Inc. earnings per share, basic and diluted for the quarter ending 2021-06-30 was -$1.47.
- Lyell Immunopharma, Inc. earnings per share, basic and diluted for the quarter ending 2020-09-30 was -$2.57.
- Lyell Immunopharma, Inc. earnings per share, basic and diluted for the quarter ending 2020-06-30 was -$8.18.
| Period end | Earnings Per Share, Basic and Diluted 3 month | Earnings Per Share, Basic and Diluted 6 month | Earnings Per Share, Basic and Diluted 9 month |
|---|---|---|---|
| 2021-09-30 | -$0.20 10-Q · filed 2021-11-12 | -$790.30 derived: net income ÷ weighted average shares · filed 2021-11-12 | -$1.66 10-Q · filed 2021-11-12 |
| 2021-06-30 | -$1.47 10-Q · filed 2021-08-12 | -$3.91 10-Q · filed 2021-08-12 | |
| 2020-09-30 | -$2.57 10-Q · filed 2021-11-12 | -$10407.92 derived: net income ÷ weighted average shares · filed 2021-11-12 | -$13.40 10-Q · filed 2021-11-12 |
| 2020-06-30 | -$8.18 10-Q · filed 2021-08-12 | -$11.14 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |